Company Overview
AnaptysBio, Inc. operates as a clinical-stage biotechnology entity dedicated to delivering immunology therapeutics for autoimmune and inflammatory diseases within the United States market. The company's product portfolio includes Rosnilimab, a selective pathogenic T cell depletor that recently completed a Phase 2b trial for the treatment of specific conditions. This organization functions within the healthcare sector, specifically the biotechnology industry, where high-risk development and specialized regulatory pathways define operational norms. With a market capitalization of $1.79B, annual revenue of $234.60M, and an employee base of 104, the firm represents a mid-sized biopharmaceutical entity with significant growth potential but limited operational scale. These financial dimensions indicate that while the company has secured substantial valuation relative to its current revenue, its position reflects the capital-intensive nature of clinical-stage development where future product approvals will be critical for sustaining its market presence.
Financial Health
The company reported revenue of $234.60M over the trailing twelve months, yet recorded a net income of -$13,232,000, highlighting a substantial gap between top-line generation and bottom-line profitability. This discrepancy reveals a cost structure heavily weighted toward research and development expenses typical of clinical-stage firms, which suppress net income despite robust sales growth. In terms of profitability metrics, the gross margin stands at 42.0%, indicating that the company retains over two-fifths of revenue after direct production costs. The operating margin is significantly higher at 61.8%, suggesting efficient management of overhead and administrative expenses, while the profit margin of -5.6% confirms that the company is currently unprofitable on a net basis. Despite the net loss, the company generated an EBITDA of $48.45M, demonstrating strong operating cash generation before interest and taxes. Furthermore, free cash flow reached $19.34M, providing the financial flexibility necessary to fund ongoing clinical trials without immediate reliance on external financing. The balance sheet shows a cash position of $311.64M against total debt of $290.64M, resulting in a debt-to-equity ratio of 781.08. Although the absolute debt load is high relative to equity, the liquidity position appears manageable given the cash reserves. The current ratio is 9.07, which indicates an extremely strong ability to cover short-term obligations with current assets. Return on equity is -24.5%, reflecting the dilutive impact of losses on shareholder equity, while return on assets is 7.1%, suggesting that the asset base is generating positive returns relative to its total value.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, whereas the forward P/E is -15.38, implying that the market prices in future earnings recovery rather than current profitability. The price-to-book ratio is 46.96, which indicates a significant market premium over the company's book value, characteristic of biotechnology firms with valuable intellectual property portfolios. Alternative valuation metrics such as the price-to-sales ratio of 7.64 and the EV/EBITDA of 36.57 suggest that investors are valuing the company based on revenue growth potential and earnings before interest, taxes, depreciation, and amortization rather than current earnings power. The stock has traded between a 52-week low of $15.40 and a 52-week high of $68.39, and without the current share price explicitly stated in the provided facts, the relative position to this range cannot be calculated. The beta value is 0.41, which means the stock exhibits lower price volatility relative to the broader market, moving with roughly 59% of the intensity of the overall index. This low beta suggests that the stock may act as a hedge against general market downturns, although the negative forward P/E complicates traditional volatility analysis in the context of earnings.
Growth & Income
Revenue growth year-over-year stands at 151.1%, demonstrating exceptional top-line expansion, while earnings growth is N/A due to the company's current unprofitable status. Since earnings growth is not applicable, the company is not growing earnings faster or slower than revenue; rather, it is in a phase where revenue expansion precedes profitability. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This structure implies that the company reinvests all available earnings and cash flow back into the business to fund clinical development and operational scaling rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined by aggressive revenue expansion and a complete retention of earnings to support future commercialization efforts.